# Relapsing-Remitting Multiple Sclerosis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/relapsing-remitting-multiple-sclerosis

> No upcoming FDA catalysts in Relapsing-Remitting Multiple Sclerosis; 4 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for Relapsing-Remitting Multiple Sclerosis?

No upcoming FDA catalysts in Relapsing-Remitting Multiple Sclerosis; 4 past events are recorded. ClinicalTrials.gov: "NCT02283853 (Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-08 (ACTUAL); Lead Sponsor Biogen; Results First Posted 2026-05-19." [Calendar and source filings](https://sec-api.dev/indications/relapsing-remitting-multiple-sclerosis)

Source: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT02283853?tab=results (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/indications/relapsing-remitting-multiple-sclerosis#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 8, 2025 | [Tecfidera (dimethyl fumarate) primary completion](https://sec-api.dev/pdufa/dimethyl) | BIIB | Relapsing-Remitting Multiple Sclerosis | completed | "NCT02283853 (Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-08 (ACTUAL); Lead Sponsor Biogen; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02283853)) |
| July 14, 2025 | [Pipe-307 dose a primary completion](https://sec-api.dev/pdufa/pipe-307) | JNJ | Relapsing Remitting Multiple Sclerosis | completed | "NCT06083753 (Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-14 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06083753)) |
| Q4 2025 | [Pipe-307 dose a topline data readout](https://sec-api.dev/pdufa/pipe-307) | CTNM | relapsing-remitting multiple sclerosis | scheduled | "- Topline data from the PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) is anticipated in the fourth quarter of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000143774925032422/ex_870706.htm)) |
| May 19, 2026 | [Tecfidera (dimethyl fumarate) topline data readout](https://sec-api.dev/pdufa/dimethyl) | BIIB | Relapsing-Remitting Multiple Sclerosis | completed | "NCT02283853 (Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-08 (ACTUAL); Lead Sponsor Biogen; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02283853?tab=results)) |

## Drugs

- [Tecfidera (dimethyl fumarate)](https://sec-api.dev/pdufa/dimethyl) (BIIB)
- [Pipe-307 dose a](https://sec-api.dev/pdufa/pipe-307) (JNJ)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/relapsing-remitting-multiple-sclerosis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Relapsing-Remitting Multiple Sclerosis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/relapsing-remitting-multiple-sclerosis

```bibtex
@misc{secapidev_indications_relapsing_remitting_multiple_sclerosis_20261116,
  title        = {Relapsing-Remitting Multiple Sclerosis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/relapsing-remitting-multiple-sclerosis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_relapsing_remitting_multiple_sclerosis_20261116","title":"Relapsing-Remitting Multiple Sclerosis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/relapsing-remitting-multiple-sclerosis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
